Cytokinetics

We are developing potential medicines to improve the healthspan of people with diseases of impaired muscle function. 2025 Great Place to Work-Certified🏅

[Cytokinetics @Cytokinetics]

Today we announced topline results from ACACIA-HCM, our Phase 3 clinical trial in non-obstructive HCM. Learn more in our press release: https://t.co/cjCZZad8W3

#Biopharma #HCM

[Cytokinetics @Cytokinetics]

New research in @JAMA_current! As a supporter of the #HCM registry, we are excited for these findings on improving risk prediction of adverse events in HCM patients.

Read more: https://t.co/Tf6MNkkQDD

#CardioX

[Cytokinetics @Cytokinetics]

We had an incredible time at #HeartFailure2026!

It was a privilege to connect with leading experts, clinicians, and advocates from around the world. We are proud to be growing our European team to further support this vital community that continues to inspire our mission.

[Cytokinetics @Cytokinetics]

Attending #HeartFailure2026 in #Barcelona? Visit us at the Cytokinetics booth to talk with our team and learn more about our research & science.

We'll be presenting data, sharing abstracts, and leading a sponsored satellite symposium.

#HeartFailure #CardioX

[Cytokinetics @Cytokinetics]

We're excited to be attending ANMCO 2026 May 7–9 in Rimini, Italy. We'll be connecting with the Italian cardiology community at this congress dedicated to sharing knowledge and innovative perspectives.

#ANMCO #CardioX

[Cytokinetics @Cytokinetics]

$CYTK: Today, we reported our first quarter 2026 financial results. Our senior management team will provide more details in a conference call at 4:30 p.m. ET. https://t.co/mw0Dg57kKL

#earnings

[Cytokinetics @Cytokinetics]

Our 3rd annual CLIMB Research Symposium is just around the corner! Taking place on May 29 in San Francisco. CLIMB brings together the scientific community to share innovative research in the field of muscle biology.

Register today: https://t.co/weYroDOwmI

#CLIMB26

[Cytokinetics @Cytokinetics]

We'll be sharing nine presentations, including a late-breaking science oral presentation, at #HeartFailure2026 in Barcelona, Spain, May 9 – 12.

Learn more: https://t.co/2ngsl8M7W5

#HeartFailure #CardioTwitter

[Cytokinetics @Cytokinetics]

We’re looking forward to attending HFA Heart Failure 2026 in Barcelona, Spain, May 9 – 12. We'll be sharing abstracts, sponsoring a satellite symposium, and connecting with attendees at our booth.

Learn more: https://t.co/EYY5PVJ4ta

#HeartFailure2026 #HeartFailure

[Cytokinetics @Cytokinetics]

Years of R&D rigor, operational planning and readiness, and thoughtful fiscal management aligned at the right time to enable fulfillment of our longstanding mission.

Read more about our progress in our 2025 annual reports: https://t.co/PkkClWJW5b

[Cytokinetics @Cytokinetics]

We're excited to be attending several clinical conferences, where we’ll be connecting with experts dedicated to advancing cardiovascular care.

#CVN2026 #AAHFN2026 #ASE2026 #CardioTwitter

[Cytokinetics @Cytokinetics]

We’re here at the 92nd Annual Meeting of the German Society of Cardiology (DGK) in Mannheim, Germany. Visit us at booth 113 to meet our team and learn more about our research & science.

#DGK #DGKJahrestagung #DGK2026JT #HCM #CardioTwitter

[Cytokinetics @Cytokinetics]

Registration is now open for our CLIMB Research Symposium taking place on May 29 in San Francisco. Hear from speakers ranging from Cytokinetics co-founder James A. Spudich, PhD, to up-and-coming researchers covering muscle biology and more. https://t.co/weYroDOwmI #CLIMB26

[Cytokinetics @Cytokinetics]

We are thrilled to be on the ground at #ACC26 this weekend, and the energy is incredible. But the real excitement? Sharing that our first approved medicine is now available for patients.

Please see full Prescribing Information, including Boxed WARNING: https://t.co/doI5Zgv009

[Cytokinetics @Cytokinetics]

We’re excited to be attending #ACC26 in New Orleans, March 28 – 30. Visit us at booth #2237 to learn more about our research & science.

We’ll also be presenting new data from our clinical research programs and hosting an industry product theater.

#HCM #CardioTwitter

[Cytokinetics @Cytokinetics]

@Christo41039478 Our MYQORZO & You Patient Support Program may be able to help eligible patients when insurance coverage is an issue. For more information, connect with a MYQORZO Navigator at 833-MYQORZO (833-697-6796) available Monday through Friday 8 AM – 8 PM ET.

[Cytokinetics @Cytokinetics]

Join us for our CLIMB Symposium on May 29 in San Francisco!

CLIMB brings together the scientific community to share innovative research in the field of muscle biology aimed at driving advancements.
Register today: https://t.co/weYroDOwmI.

#CLIMB26

[Cytokinetics @Cytokinetics]

$CYTK: Today, we reported our fourth quarter 2025 financial results. Our senior management team will provide more details in a conference call at 4:30 p.m. ET.
https://t.co/SJ7jiC5Dvw

[Cytokinetics @Cytokinetics]

@JainySavlaMD @JainySavlaMD Please call 833-MYQORZO or (833-697-6796).

[Cytokinetics @Cytokinetics]

Our new medicine for the treatment of adults with symptomatic oHCM is now FDA-approved. This approval is the result of years of clinical research and collaboration with the HCM community, and most importantly, marks progress for patients.

#HCM #CardioTwitter